Francisco Javier Alvarez Gutierrez
Overview
Explore the profile of Francisco Javier Alvarez Gutierrez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dominguez-Ortega J, Mullol J, Alvarez Gutierrez F, Miguel-Blanco C, Castillo J, Olaguibel J, et al.
J Allergy Clin Immunol Glob
. 2023 Nov;
3(1):100174.
PMID: 37915724
Background: Increasing evidence supports the united airway disease concept for the management of upper and lower respiratory tract diseases, particularly in patients with asthma and chronic rhinosinusitis with nasal polyps...
2.
Carretero Gracia J, Rodriguez Fernandez F, Gomez Saenz J, Molina Paris J, Gomez Ruiz F, Lopez Carrasco V, et al.
Open Respir Arch
. 2023 Jul;
3(4):100131.
PMID: 37496835
Asthma is one of the most prevalent chronic diseases in Spain. In 2019, the Spanish Society of Allergology and Clinical Immunology (SEAIC), the Spanish Society of Primary Care Physicians (SEMERGEN),...
3.
Perpina Tordera M, Alvarez Gutierrez F, Blanco Aparicio M
Arch Bronconeumol
. 2022 Apr;
58(5):390-391.
PMID: 35437205
No abstract available.
4.
Blanco Aparicio M, Alvarez Gutierrez F, Casas Maldonado F
Arch Bronconeumol (Engl Ed)
. 2019 Nov;
56(5):269-270.
PMID: 31668772
No abstract available.
5.
Entrenas Costa L, Casas-Maldonado F, Soto Campos J, Padilla-Galo A, Levy A, Alvarez Gutierrez F, et al.
Pharmacoecon Open
. 2019 Jan;
3(3):333-342.
PMID: 30684255
Background: Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. Aims: The aim of this study was...
6.
Castillo Vizuete J, Sastre J, Del Cuvillo Bernal A, Picado C, Martinez Moragon E, Ignacio Garcia J, et al.
Arch Bronconeumol (Engl Ed)
. 2018 Nov;
55(3):146-155.
PMID: 30449614
The aim of this review is to assist pulmonologists in the management of diseases involving both the upper and lower respiratory tract that are linked by a common, interrelated epidemiology,...
7.
Predictive factors for moderate or severe exacerbations in asthma patients receiving outpatient care
Alvarez Gutierrez F, Ferrer Galvan M, Medina Gallardo J, Mancera M, Romero Romero B, Romero Falcon A
BMC Pulm Med
. 2017 May;
17(1):77.
PMID: 28464895
Background: Asthma exacerbations are important events that affect disease control, but predictive factors for severe or moderate exacerbations are not known. The objective was to study the predictive factors for...
8.
Ferrer Galvan M, Alvarez Gutierrez F, Romero Falcon A, Romero Romero B, Saez A, Medina Gallardo J
Respir Med
. 2017 Apr;
126:26-31.
PMID: 28427546
Introduction: Asthma control includes the control of symptoms and future risk. We sought to evaluate the usefulness of the degree of spirometric reversibility of the forced expiratory volume in one...
9.
Alvarez Gutierrez F, Ferrer Galvan M, Ruiz Bernal A, Medina Gallardo J, Romero Romero B, Saez Diaz A, et al.
Addiction
. 2015 Oct;
111(3):545-51.
PMID: 26498919
Aims: To identify factors predicting long-term relapse to smoking in people attending smoking treatment services who have maintained at least 1 year abstinence. Design: Observational, prospective study with multiple logistic...
10.
Perpina Tordera M, Garcia Rio F, Alvarez Gutierrez F, Cisneros Serrano C, Compte Torrero L, Entrenas Costa L, et al.
Arch Bronconeumol
. 2013 Jul;
49(10):432-46.
PMID: 23896599
No abstract available.